# A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

> **NCT05489705** · — · RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 1600 (estimated)

## Conditions studied

- Obstructive Hypertrophic Cardiomyopathy

## Interventions

- **DRUG:** Mavacamten
- **DRUG:** Non-mavacamten symptomatic oHCM therapy

## Key facts

- **NCT ID:** NCT05489705
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-16
- **Primary completion:** 2029-08-17
- **Final completion:** 2029-08-17
- **Target enrollment:** 1600 (ESTIMATED)
- **Last updated:** 2025-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05489705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05489705, "A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05489705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*